AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38330987 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 2.4 mg
Number of subjects: 387
Study 38330987 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 3.6 mg
Number of subjects: 387
Study 38330987 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 4.8 mg
Number of subjects: 387
Study 38330987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 38330987 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide
Number of subjects: 387
Study 38330988 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 375
Study 38330988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 38331027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period (after implementation of checklist)
Number of subjects: 1108
Study 38331204 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous AI-based CADx optical diagnosis of diminutive polyps
Number of subjects: 467
Study 38331204 — intervention group
Group type: COMPARATOR
Intervention: AI-assisted human (AI-H) optical diagnosis of diminutive polyps
Number of subjects: 467
Study 38331348 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine syrup (100 mg/kg/d) for 15 days
Number of subjects: 98
Study 38331348 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 98
Study 38331400 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA15 15 mg once daily
Number of subjects: 639
Study 38331400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 38331453 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38331586 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fatal overdose experience
Number of subjects: 771
Study 38331586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior overdose experience
Number of subjects: 771
Study 38331586 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance(s) used during worst overdose experience
Number of subjects: 771
Study 38331586 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and cannabis group
Number of subjects: 771
Study 38331586 — intervention group
Group type: COMPARATOR
Intervention: Alcohol with other substance(s) group
Number of subjects: 771
Study 38331586 — intervention group
Group type: COMPARATOR
Intervention: Other substance(s) only group
Number of subjects: 771
Study 38331709 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 7832
Study 38331793 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal transradial access (dTRA)
Number of subjects: 726
Study 38331793 — intervention group
Group type: COMPARATOR
Intervention: Conventional transradial access (TRA)
Number of subjects: 726
Study 38331799 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory disorders group (ODG)
Number of subjects: 56
Study 38331799 — intervention group
Group type: COMPARATOR
Intervention: Normosmic group (NG)
Number of subjects: 56
Study 38331799 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived olfactory evaluation in NG
Number of subjects: 56
Study 38331799 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived olfactory evaluation in ODG
Number of subjects: 56
Study 38331799 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical tests and self-perceived olfactory evaluations
Number of subjects: 56
Study 38331799 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression dimensions
Number of subjects: 56
Study 38331822 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention program for childcare teachers, including a 6-month training program on healthy lifestyles (diet, sleep, physical activity, sedentary behavior)
Number of subjects: 344
Study 38331822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study 38331891 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole propionate (ImP) levels in chronic HF patients
Number of subjects: 166
Study 38331891 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 166
Study 38331891 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of intestinal permeability and systemic inflammation
Number of subjects: 166
Study 38331900 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 32
Study 38331900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 32
Study 38331900 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia
Number of subjects: 32
Study 38332008 — intervention group
Group type: EXPERIMENTAL
Intervention: InTandem (autonomous neurorehabilitation system)
Number of subjects: 0
Study 38332008 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38332403 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal intensity gradient (SIG) from TOF-MRA
Number of subjects: 0
Study 38332403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase contrast magnetic resonance (PC-MR)
Number of subjects: 0
Study 38332428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients
Number of subjects: 107
Study 38332436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 1027
Study 38332436 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab (GUS)
Number of subjects: 1027
Study 38332440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled fecal immunochemical testing (FIT) and social determinants of health (SDOH) screening
Number of subjects: 34588
Study 38332440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bundled FIT-SDOH screening)
Number of subjects: 34588
Study 38332460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 689
Study 38332460 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF)
Number of subjects: 689
Study 38332651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 635
Study 38332651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 635
Study 38332651 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment
Number of subjects: 635
Study 38332651 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose hydroxyurea
Number of subjects: 635
Study 38332651 — intervention group
Group type: COMPARATOR
Intervention: Dose escalation hydroxyurea
Number of subjects: 635
Study 38332984 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) for 20 minutes at 2 mA for 10 daily sessions
Number of subjects: 0
Study 38332984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with tDCS
Number of subjects: 0
Study 38332984 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 38333020 — intervention group
Group type: EXPERIMENTAL
Intervention: Callergin (iota-carrageenan nasal spray)
Number of subjects: 42
Study 38333020 — intervention group
Group type: COMPARATOR
Intervention: VisAlpin (comparator product)
Number of subjects: 42
Study 38333020 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study 38333368 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with clinically relevant fatigue at baseline
Number of subjects: 3038
Study 38333368 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with cognitive deficits
Number of subjects: 3038
Study 38333368 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for non-recovery from fatigue
Number of subjects: 3038
Study 38333368 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for cognitive non-recovery
Number of subjects: 3038
Study 38333368 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 reinfection
Number of subjects: 3038
Study 38333728 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality plus ERAS protocol
Number of subjects: 0
Study 38333728 — intervention group
Group type: COMPARATOR
Intervention: ERAS protocol alone
Number of subjects: 0
Study 38333889 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65Ab positivity
Number of subjects: 100
Study 38333967 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR+LEAP augmentation
Number of subjects: 253
Study 38333967 — intervention group
Group type: COMPARATOR
Intervention: ACLR alone
Number of subjects: 253
Study 38334147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (5 mg/m²)
Number of subjects: 575
Study 38334147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus intra-articular glucocorticoid (IAGC) therapy
Number of subjects: 575
Study 38334147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 575
Study 38334147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 38334413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.1% solution
Number of subjects: 1162
Study 38334413 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group (control)
Number of subjects: 1162
Study 38334470 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose positron emission mammography (PEM) with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose
Number of subjects: 0
Study 38334470 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study 38334499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 38334499 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BLYS agents, novel calcineurin inhibitors, CD20 blockade, and antiinterferon agents
Number of subjects: 0
Study 38334499 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for induction and maintenance treatment of lupus nephritis
Number of subjects: 0
Study 38334943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gene mutations (including SPINK1, PRSS1, CTRC, CFTR)
Number of subjects: 160
Study 38334943 — intervention group
Group type: COMPARATOR
Intervention: Patients without gene mutations
Number of subjects: 160
Study 38334943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gene mutations (including SPINK1)
Number of subjects: 160
Study 38334943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CP-susceptibility gene mutations
Number of subjects: 160
Study 38334943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SPINK1 mutations
Number of subjects: 160
Study 38334953 — intervention group
Group type: EXPERIMENTAL
Intervention: ALD group
Number of subjects: 178
Study 38334953 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary sucralose
Number of subjects: 178
Study 38334953 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour sucralose/lactulose ratio
Number of subjects: 178
Study 38334953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 178
Study 38334953 — intervention group
Group type: COMPARATOR
Intervention: Five-hour urinary lactulose/mannitol ratio
Number of subjects: 178
Study 38335019 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTCare platform
Number of subjects: 120
Study 38335019 — intervention group
Group type: COMPARATOR
Intervention: Standard of care process for survivorship
Number of subjects: 120
Study 38335023 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellinks intervention with remote health coaching, pulmonary rehabilitation, and group education; 6 coaching sessions in the first 12 weeks, followed by reduced frequency or discontinuation in the second 12 weeks.
Number of subjects: 141
Study 38335032 — intervention group
Group type: EXPERIMENTAL
Intervention: brepocitinib 45 mg
Number of subjects: 194
Study 38335032 — intervention group
Group type: EXPERIMENTAL
Intervention: zimlovisertib 400 mg
Number of subjects: 194
Study 38335032 — intervention group
Group type: EXPERIMENTAL
Intervention: ropsacitinib 400 mg
Number of subjects: 194
Study 38335032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 194
Study 38335169 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial reorganization® (MRT) for 10 min, once a week for 6 weeks
Number of subjects: 75
Study 38335169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham sSG (classical massage for 10 min, once a week for 6 weeks)
Number of subjects: 75
Study 38335169 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention
Number of subjects: 75
Study 38335169 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial reorganization® (MRT)
Number of subjects: 75
Study 38335228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric dietary intervention for 6 months
Number of subjects: 12
Study 38335386 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment (herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, Chuna therapy, KM physiotherapy)
Number of subjects: 86
Study 38335386 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 86
Study 38335467 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines
Number of subjects: 0
Study 38335467 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38335474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg BID
Number of subjects: 223
Study 38335474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg QD
Number of subjects: 223
Study 38335474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg QD
Number of subjects: 223
Study 38335474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to evobrutinib 25 mg QD after week 24)
Number of subjects: 223
Study 38335474 — intervention group
Group type: COMPARATOR
Intervention: Open-label dimethyl fumarate (DMF) 240 mg BID
Number of subjects: 223
Study 38335473 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (dordaviprone) monotherapy
Number of subjects: 50
Study 38335499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone 6 mg/kg/d
Number of subjects: 121
Study 38335499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone 2 mg/kg/d
Number of subjects: 121
Study 38335499 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 121
Study 38335499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 38335531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 92
Study 38335850 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (electron beam and photon beam therapies)
Number of subjects: 2
Study 38335935 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)-driven interventions
Number of subjects: 475
Study 38335935 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 475
Study 38335978 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (150 mg, 100 mg for Asian patients) and cyclosporin A (10 mg/kg per day)
Number of subjects: 54
Study 38335978 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag and cyclosporin A
Number of subjects: 54
Study 38336284 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute liver failure (ALF) at admission
Number of subjects: 418
Study 38336284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic hepatitis (HH) at admission
Number of subjects: 418
Study 38336284 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG clearance test
Number of subjects: 418
Study 38336284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis factors
Number of subjects: 418
Study 38336284 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 28 mortality
Number of subjects: 418
Study 38336367 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free symptomatic remission (Mayo RBS=0) (group 1)
Number of subjects: 660
Study 38336367 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free endoscopic remission (MES ≤1) and symptomatic remission (group 2)
Number of subjects: 660
Study 38336367 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free histologic remission (Geboes score <2B.0), endoscopic remission and symptomatic remission (group 3)
Number of subjects: 660
Study 38336521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication tool
Number of subjects: 0
Study 38336521 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38336516 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated 2022 guidelines for preoperative transthoracic echocardiography (TTE)
Number of subjects: 15529
Study 38336516 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated 2022 guidelines for preoperative stress imaging
Number of subjects: 15529
Study 38336516 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of NT-proBNP for risk estimation
Number of subjects: 15529
Study 38336516 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to updated guidelines
Number of subjects: 15529
Study 38336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental toothpaste (0.2% sodium hyaluronate, 67% sodium bicarbonate, 0.221% sodium fluoride)
Number of subjects: 110
Study 38336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control toothpaste (67% sodium bicarbonate, 0.221% sodium fluoride)
Number of subjects: 110
Study 38336635 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride toothpaste (negative control)
Number of subjects: 110
Study 38336635 — intervention group
Group type: COMPARATOR
Intervention: Experimental toothpaste vs Positive control
Number of subjects: 110
Study 38336649 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 1865
Study 38336649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 1865
Study 38336649 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological wellbeing during strict containment measures
Number of subjects: 1865
Study 38336689 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (DESO)
Number of subjects: 5
Study 38336689 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LEVO)
Number of subjects: 5
Study 38336691 — intervention group
Group type: EXPERIMENTAL
Intervention: SCREEN package intervention
Number of subjects: 302
Study 38336691 — intervention group
Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 302
Study 38336691 — intervention group
Group type: EXPERIMENTAL
Intervention: First telephonic follow-up
Number of subjects: 302
Study 38336691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean duration to reach referral centre
Number of subjects: 302
Study 38336731 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPare for Work Stage 1 intervention (strength-based case management and facilitated PrEP linkage)
Number of subjects: 0
Study 38336731 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPare for Work Stage 2 intervention (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders)
Number of subjects: 0
Study 38336731 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 38336779 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based primary care (HBPC) dementia care intervention
Number of subjects: 50
Study 38336793 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit plus one-time economic incentive
Number of subjects: 1332
Study 38336793 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term counseling and economic incentive program
Number of subjects: 1332
Study 38336803 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) + Making Connections Intervention (MCI)
Number of subjects: 60
Study 38336803 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A)
Number of subjects: 60
Study 38336815 — intervention group
Group type: EXPERIMENTAL
Intervention: VagiBIOM suppository
Number of subjects: 66
Study 38336815 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 66
Study 38336861 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 and LAG-3 blockade
Number of subjects: 1
Study 38337191 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)-based method for assessing prognostic indicators
Number of subjects: 310
Study 38337191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor burden greater than the median
Number of subjects: 310
Study 38337375 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller blade laryngoscope
Number of subjects: 110
Study 38337375 — intervention group
Group type: COMPARATOR
Intervention: External pressure application
Number of subjects: 110
Study 38337375 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI over 44.244 kg/m
Number of subjects: 110
Study 38339248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-Azacitidine (3 mg/kg/dose)
Number of subjects: 13
Study 38339248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-Azacitidine
Number of subjects: 13
Study 38340111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 8
Study 38340111 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine treatment
Number of subjects: 8
Study 38340127 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 65
Study 38340127 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 65
Study 38340159 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of peripheral oxygen saturation (SpO2) during the 6-Minute Walk Test
Number of subjects: 0
Study 38340330 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS) pacing during tilt test
Number of subjects: 17
Study 38340349 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy (within 90 days after radium-223)
Number of subjects: 182
Study 38340349 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed chemotherapy (more than 90 days after radium-223)
Number of subjects: 182